ClinicalTrials.gg
CompletedNCT00959218Updated Feb 3, 2012

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

A Phase 3 interventional study of Dronabinol and Placebo in Central Neuropathic Pain in Multiple Sclerosis, sponsored by Bionorica Research GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Bionorica Research GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 252 studies in Multiple Sclerosis with a site in Germany — 27 open to participants now, 49 under way, 15 of them phase 3. Multiple Sclerosis · Germany.

Enrollment
99th of 190
240 · median 258
Started
2007
with 18 others
Phase 3
78 of 252
5 open now
Registered
60th of 252
by date

Among the 252 studies in Multiple Sclerosis with a site in Germany, this one is the 99th largest by enrollment of the 190 interventional ones that give a count, is one of 19 that started in 2007, is one of 78 in phase 3, and was the 60th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

27 of the 252 studies in Multiple Sclerosis with a site in Germany are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Multiple Sclerosis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

Read the detailed description

Multiple sclerosis (MS) is in all probability an autoimmune disease causing severe neurological disability due to inflammation and degeneration in the central nervous system (CNS). MS affects over 1 million people worldwide. Central neuropathic pain is associated with approximately 30% of all patients with MS. MS-accompanying pain has a major impact on the patients' quality of life as usual conventional analgesics are little effective. The aim of this clinical study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

03

Conditions studied

  • Central Neuropathic Pain in Multiple Sclerosis

Browse trials for

Keywords

  • Dronabinol
  • (-)trans-delta9-tetrahydrocannabinol
  • central neuropathic pain
  • multiple sclerosis
  • analgesic
  • Central neuropathic pain related to multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis acc. to McDonald diagnostic criteria
  • EDSS score between 3 and 8 (incl.)
  • Patients who are in a stable phase of multiple sclerosis
  • Patients with MS-related central neuropathic pain for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Severe concomitant diseases
  • Certain concomitant therapies (in particular: pain influencing concomitant therapies)
  • Dronabinol intake within the last 12 months prior to study entry or Marihuana use within one month prior to study entry
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Dronabinol

    Drug: Dronabinol

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • oral solution, daily dose up to 15 mg, treatment up to 2.5 years

    Also known as: (-)trans-delta9-tetrahydrocannabinol

  • DrugPlacebo

    oral solution

06

What researchers measure

Primary outcomes

  1. Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary

    Time frame: max. 2.5 years

Secondary outcomes

  1. Likert Numerical Rating Scale pain relief

    Time frame: max. 2.5 years

  2. Pain-related sleep interference

    Time frame: max. 2.5 years

  3. SF-36 (QoL-questionnaire)

    Time frame: max. 2.5 years

  4. Intake of rescue medication

    Time frame: 48 weeks

07

Study locations

1 site
  • Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie
    Luedenscheid, 58515, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2009
First posted
Aug 14, 2009
Start
Jun 2007
Primary completionActual
Mar 2010
CompletionActual
Apr 2010
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00959218
Lead sponsor
Bionorica Research GmbH
Responsible party
Sponsor
First posted
Aug 14, 2009
Start date
Jun 2007
Primary completion
Mar 2010
Completion
Apr 2010
Last update
Feb 3, 2012

Study contacts

Sebastian Schimrigk, MD
principal investigator · Klinikum Luedenscheid

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion